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Abstract
The central nervous system (CNS) and the gastrointestinal (GI) tract develop in parallel
and  communicate  with  each  other  throughout  life  using  neural,  endocrine,  and
immune pathways, giving rise to the concept of a ‘gut‐brain axis’ in which both organ
systems intimately interact. Fundamental to the axis is the GI microbiome, which is
the  collective  genomic  aggregate  of  bacteria  and other  microorganisms that  dwell
within the lumen of the GI tract. Increasing evidence gathered from animal models
and  human  studies  demonstrates  that  perturbation  of  the  microbiome,  otherwise
known as dysbiosis, can lead to specific neurological and psychiatric disorders. This
chapter will provide a brief review of the literature that reveals the influence of the
microbiome in CNS disease and provide perspectives in treatment through modifica‐
tion of the microbiome.
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1. Introduction to the brain-gut-microbiome axis
The human microbiome has emerged as an entity with a tremendous degree of influence in
health and disease.1 Bacteria within the GI tract perform a wide range of symbiotic functions
for their host, which range from digestion and the production of bioactive metabolites to
influencing the healthy development and function of the immune system [1, 2]. All of these
local effects on the GI tract have the ability to impact the brain through neural connections,
1 For the purposes of this chapter, the microbiome mentioned herein refers to the combined aggregate of bacteria,
viruses, fungi, archaea, and protista.
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such as the vagus nerve, and by endocrine means [3, 4]. The awareness of this two-way
interaction between the gut and the brain has now provided more explanations for some
conditions otherwise labeled as ‘functional disorders’ and has also laid fertile ground for the
discovery of new treatment modalities in modulating the microbiome in treating CNS disease
[5–7].
Significant development of the microbiome begins at the time of delivery. Vaginally, born
infants are colonized by maternal fecal and vaginal microorganisms, whilst those born by
Cesarean section are colonized by skin flora [8, 9]. Although the dogma has been that the
antenatal intrauterine environment is sterile, this notion has been challenged by several
findings, most notably that meconium contains bacterial colonies. Therefore, this implies that
the influence of the microbiome may extend into the prenatal period [10, 11]. Following birth,
the microbiome adapts according to factors such as dietary intake, antibiotic use, and living
conditions. As the CNS and microbiome develop in parallel, significant changes in the
microbiota occur at critical neurodevelopment time periods [12, 13]. Disruptions in the
evolutionary progression of the microbiome may therefore have a lasting impact on the healthy
development of the brain and vice versa because of this close interaction between the two
systems.
The term ‘dysbiosis’ refers to an imbalance of microorganisms within the mucosal flora.
Hepatic encephalopathy is the archetypal example of how a GI dysbiosis can result in CNS
damage. Liver cirrhosis results in a distinct microbiota signature that differs significantly from
healthy, control subjects [14]. Accumulation of toxic mediators, such as ammonium produced
by urease-producing bacteria, enters the portal circulation. Blood ammonium concentrations
rise, cross the blood-brain barrier, and accumulate within the brain leading to astrocytic
damage and cerebral edema [15–17]. Curiously, however, treatment with the oral antibiotic
rifaximin does not cause clinical improvement through changing the proportions of bacteria
in the microbiome, but rather, the improvement in endotoxemia and cognition appears to be
through modulation of bacterial metabolism [18–21]. Therefore, derangements of the micro-
biome that result in CNS dysfunction are not limited to constitutional changes but may also
be influenced by its metabolic activity.
2. The influence of the microbiome in multiple sclerosis
2.1. Epidemiology and pathogenesis
Multiple sclerosis (MS) is the most common CNS demyelinating disease and is classically
depicted by the acquisition of discrete demyelinating plaques within the grey and white
matter of the CNS [22–24]. The acute MS plaque is characterized by infiltration of inflam-
matory cells with concomitant demyelination and edema [25]. Perivascular lymphocytic
cuffing comprised predominantly of T cells is seen. There is a reactive astrogliosis with var-
iable amounts of oligodendrocyte apoptosis within the plaque [26]. Over time, the plaques
become sclerotic, representing the final pathological event at that location after a period of
marked inflammation, astrogliosis, demyelination, remyelination, and axonal loss.
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Despite this common pathological hallmark of the disease, MS is remarkably heterogeneous
in terms of clinical presentation and prognosis [27]. Furthermore, the exact pathogenesis still
remains poorly understood, although it is clear that both genetics and the environment have
significant influences in the onset of MS and a complex interplay exists between these elements
[28, 29]. Certainly, inflammation plays a key role in the pathophysiology of the disease. Most
researchers favor an autoimmune hypothesis whereby autoreactive immune cells targeting
myelin antigens are activated, likely incited by an environmental trigger [30].
Migrational studies have provided insight into how environmental changes may influence the
risk of development of MS. Generally, populations further away from the equator have an
increased risk of developing MS than those closer to the equator [31, 32]. Many studies have
demonstrated that people migrating from high-risk areas to low-risk areas can be at sustained
risk if the migration occurred after a certain critical age point [33]. Conversely, if the age of
migration is younger than the critical age point, the individual is conferred the risk of the new
region. The human microbiome is recognized to exhibit great geographical variation between
populations and the local environment has a marked influence on the development of the
microbiota [34, 35]. Given that the microbiota influences neurodevelopment and immunity
early in life, one can speculate that this may explain why the conferred migrational risk of MS
is age-dependent.
The first suggestion that MS may be related to hygienic living conditions was reported by
Liebowitz et al. in 1966 [36]. By examining the degree of crowded living conditions, they found
that the incidence of MS was higher in those that are more sanitary. The hygiene hypothesis,
formulated later by Strachan in 1989, proposed that allergy and autoimmune diseases are, at
least in part, the consequence of inadequate immune stimulation against pathogens during
the early years of life that causes aberrant responses to self in later years [37, 38].
One MS epidemic occurred during the British occupation of the Faroe Islands during World
War II. Prior to the arrival of British troops in 1940, there were no documented cases of MS in
the native born Faroese on the islands. After 1943, there were four MS epidemics and the
patients were located in proximity to the British encampments [39, 40]. The conclusion was
that somehow the British troops had introduced an unknown pathogenic organism into the
islands. Interestingly, the incidence of several infections increased during the occupation that
coincided with MS epidemics, notably gastroenteritis and mumps infections, suggesting an
association between MS and dysbiosis [41].
Aside from geographical predispositions for MS, other risk factors such as obesity, cigarette
smoking, female sex, and low vitamin D levels are all associated with differences in the
composition and/ or metabolic activity of the microbiota [42–49]. These epidemiological
findings insinuate a potential role for the human microbiome in predisposing MS.
2.2. Bacterial dysbiosis and MS
Some of the initial indications that the GI microbiota may play a role in the pathogenesis of
MS arose from work on experimental allergic encephalomyelitis (EAE) in germ-free (GF)
mice. For decades, EAE has been used extensively as an animal model of demyelinating
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disease in which exposure to CNS myelin components, such as spinal cord homogenate or
specific myelin proteins, triggers a T‐cell‐mediated autoimmune response that leads to CNS
demyelination [50, 51]. Although there are similarities to relapsing remitting MS, there are
notable differences that have been reviewed elsewhere (refer to Sriram and Steiner for a
detailed review [50]).
Evidence that the gut microbiota can influence autoimmunity has been gathered from
experiments that contrast conventionally housed animals with a normal composition of
microbiota [also known as specific pathogen free (SPF) or conventionally colonized (CC)], and
those maintained in a sterile environment [germ‐free (GF) animals], thus removing the
possibility of postnatal colonization of their GI tract. The absence of gut microbiota at birth
affects the gut‐associated lymphoid tissue (GALT), such that GF mice have hypoplastic Peyer’s
patches and mesenteric lymph nodes. Furthermore, the lymph nodes have fewer germinal
centers and IgA‐producing plasma cells than normally present in controls [49, 52]. Beyond the
GI tract, the spleen and lymph nodes are also poorly developed [53]. This maldevelopment of
the lymphoreticular system provides an explanation as to why GF mice are more prone to
infection and why the risk of developing autoimmune disease is modified [54]. The gut
microbiome has been shown to influence the probability of developing EAE in GF and SPF
mice. Berer et al. showed that in SJL/J mice that have autoreactive CD4 T cells to myelin
oligodendrocyte protein, the presence of the GI microbiota promoted the development of EAE
[55]. Furthermore, the absence of GI microorganisms in GF mice and the consequent limited
production of TH17 cells within the GI tract and spleen appear to be protective against EAE
unlike in controls [56, 57]. When segmented filamentous bacteria, which are known to induce
the production of TH17 cells, are inoculated into the GF mice, these animals developed EAE
with antigenic stimulation, demonstrating that specific bacterial species within the gut
microflora can predispose autoimmune demyelinating disease [56].
Several studies have demonstrated changes in the abundances of various bacterial taxa in MS
compared with controls. Miyake et al. investigated fecal samples collected during the remis‐
sion phase from patients with relapsing remitting MS and demonstrated 21 species that were
significantly different in relative abundance [58]. Fourteen of these species belonged to the
Clostridia clusters XIVa and IV, which were reduced in MS patients and are recognized to have
an anti‐inflammatory role [59]. Furthermore, Bacteriodes and Prevotella species were less
prevalent in MS, although the exact pathogenic significance of this is yet defined. Of note,
however, they did not discuss the possible confounding influence of medical therapy that may
have been administered to these patients.
Rumah et al. identified Clostridium perfringens type B in the stool of a patient 3 months after
the onset of MS symptoms [60]. C. perfringens B has the capability of producing Epsilon toxin
(ETX), which can cross the blood‐brain barrier and have toxicity to oligodendrocytes, thus
providing a possible mechanism for demyelination in MS [61, 62]. Their analysis also revealed
a reduced frequency of C. perfringens A in the GI tract of MS patients and that ETX reactivity
was ten times more common than in controls. Another group identified a significantly
increased Archaea (Methanobrevibacteriaceae) in MS contrasted with controls [63]. Methanobre‐
vibacter smithii is considered to be strongly immunogenic and may be pro‐inflammatory in the
The Gut Microbiome - Implications for Human Disease44
host. The same researchers also identified several organisms that were anti‐inflammatory and
were seen in a lower abundance in MS. Significant differences in microbiota in Proteobacteria,
such as enrichment of Shigella and Escherichia, were also observed in pediatric MS when
compared with controls [64].
2.3. Viral etiology
Many viruses have been implicated as risk factors for the development of MS [65]. Perhaps
the most discussed has been the Epstein‐Barr virus (EBV), which can be present in the oral
microbiome and can be transmitted by saliva [66]. Humans are the obligate host for EBV
and while many healthy controls are infected, nearly all patients with MS have seropositiv‐
ity for EBV [67]. Furthermore, infectious mononucleosis (IM) resulting from EBV infection
doubles the risk of developing MS. Similarly, a recent meta‐analysis revealed significant
associations between anti‐EBNA (EBV nuclear antigen) IgG positivity, infectious mononu‐
cleosis, and smoking in conferring an increased risk of developing MS [68–70].
Several research findings have identified the presence of EBV within B cells from MS pa‐
tients. One study identified the presence of EBV latent proteins being expressed in B cell
follicles within the cerebral meninges and that the infiltrating B cells had EBV infection [71].
Interestingly, the cerebrospinal fluid (CSF) in MS is usually associated with oligoclonal
bands, which is the product of IgG secretion from clonally expanded B cells [72]. Screening
of these oligoclonal antibodies has identified BRRF2 and EBNA‐1, which are EBV‐related
proteins, as possible targets of the CSF IgG immune response [73]. Exactly, how EBV fits
into the pathogenesis of MS remains to be determined; however, its association with the oral
microbiome in MS is evident.
2.4. Altering the microbiome-protection against MS by helminth infection
Certain helminthic infections appear to reduce the risk of developing MS [74]. Infection with
Trypanosoma cruzi and Paracoccidiodes brasiliensis in MS patients causes lymphocytes to pro‐
duce higher amounts of interleukin‐10 (IL‐10) and neurotrophic factors, such as brain‐de‐
rived neurotrophic factor (BDNF) and nerve growth factor (NGF), in comparison with
controls [75]. In MS, there is usually a low amount of IL‐10 secretion favoring a TH1 re‐
sponse, rather than a TH2 response as is present in helminthic infections [76]. Trichuris suis is
a helminth that has efficacy when administered orally in inflammatory bowel disease (IBD).
Treatment with this helminth in MS is associated with elevated IL‐4 and IL‐10 as well as
radiological improvements on MRI [77]. Another group demonstrated reduction in IFN‐γ
and IL‐2 as well as an increase in IL‐10 and IL‐4 in secondary progressive MS following
Trichuris suis administration, suggestive of a shift toward a TH2 response [78]. In summary,
therapeutic manipulation of the gut microbiome that favors an overall anti‐inflammatory
phenotype appears to have great promise in the treatment of MS. Further trial data are
needed in this field to evaluate its efficacy and safety.
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3. Parkinson’s disease (PD)
PD typically manifests with bradykinesia, postural instability, and resting tremor that re-
sults from progressive neurodegeneration within the basal ganglia that is associated with
abnormal α-synuclein accumulation and Lewy body formation [79, 80]. Until recently, it was
thought that PD originated within the CNS, in which the pathological protein α-synuclein
spread from the dorsal motor nucleus of the vagus to involve the basal ganglia and thence-
forth the cerebral hemispheres [81]. However, the characteristic pathology has since been
found in tissues outside of the CNS. Slow transit constipation is now well recognized to be a
common finding that predates the motor symptoms in PD and can be present many years
prior to diagnosis [82–84].
Findings from autopsy and surgical pathology studies have demonstrated the presence of
phosphorylated α-synuclein in the sublingual glands and within Auerbach’s and Meissner’s
plexuses of the enteric nervous system [85–87]. Consistent with these findings, GI pathology
and concomitant symptoms predate motor features by at least 2 years [88, 89]. Transmission
of α-synuclein from neuron to neuron has been elegantly shown in a rotenone animal model
of PD wherein ingestion of rotenone causes release of α-synuclein and retrograde spread
toward the brainstem; hemitransection of the vagal nerve, however, protects against ipsilateral
synuclein pathology [90]. Similarly, neuronal transmission of α-synuclein occurs in human
mesencephalic fetal transplants of PD patients in which α-synuclein is detected within the
grafted cells at postmortem examination [91, 92]. The vagus nerve can therefore act as a conduit
for the proteopathic spread of α-synuclein from the periphery to the brainstem. In a novel
retrospective study, Svensson et al. showed a reduction in PD risk in patients who had truncal
vagotomy compared with super-selective vagotomy and between truncal vagotomy and the
general population [93]. While the study did not reach statistical significance, the complete
severance of neural bidirectional communication between the GI tract and the brain may be
beneficial in preventing the proteopathic spread of α-synuclein and hence avert PD neurode-
generation that might otherwise be inevitable.
Several pieces of data suggest that the microbiome has an involvement in PD. Scheperjans and
colleagues demonstrated in a case control study of PD that Prevotellaceae species were
significantly reduced whilst Enterobacteriaceae species were increased in patients with motor-
predominant rather than tremor-predominant PD [94]. Furthermore, the quantity of Entero‐
bacteriaceae correlated with the degree of postural instability. However, the question remains
as to whether the dysbiosis is a consequence or cause of gastrointestinal dysmotility and also
how this could influence the production, aggregation, or release of α-synuclein within the GI
tract. Regardless of the microbiome’s significance in the pathogenesis of PD, bacterial over-
growth that occurs in a proportion of patients with GI dysmotility can influence the sympto-
matic response to drug treatment. Malabsorption of drugs, in particular levodopa, is the
probable reason for the increased motor fluctuations seen in this dysbiosis. Administration of
rifaximin has shown improvement in these cases [95, 96].
The oral and nasal microbiota may also be relevant in PD and require investigation. The
nucleus of the glossopharyngeal nerve exhibits α-synuclein deposits, and similarly to the
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vagus, the glossopharyngeal nerve may act as a route for peripheral entry of PD pathology
into the brain. Furthermore, the olfactory bulb is frequently affected by PD pathology prior to
the onset of motor symptoms and this is an explanation for the often prodromal anosmia [97].
Whether there is a dysbiosis in the oral or nasal cavity has yet to be ascertained, but may offer
clues as to why PD pathology occurs in these other peripheral anatomic sites.
4. The role of the microbiome in psychiatric disease
The impact of the GI microbiome on human behavior and psychiatric disease is complex, but
there are several observations that demonstrate strong associations between the two entities.
First, anxiety and depression frequently co-exist with chronic gut disorders [98–102]. Second,
mouse models of GI infection demonstrate elevated levels of anxiety-like behavior and
alterations in CNS biochemistry [103]. Third, it was realized decades ago that stress occurring
early in life or later in adulthood can alter the microbial composition of the gut [104]. More
recent investigations conducted in animal models, and human patients have delved deeper
into these associations and have attempted to elucidate how the commensal microbiome
influences behavior.
The hypothalamic-pituitary-adrenal (HPA) axis is fundamental to the stress response, and
endocrine disturbances of this axis have been attributed to depression and anxiety. In patients
with severe depression, overactivation of the HPA axis causes hyper-secretion of catechola-
mines, corticotropin-releasing factor (CRF), and vasopressin [105]. Patients with depression
often show elevated plasma cortisol levels, elevated CRF concentrations within the CSF and
increased limbic concentrations of CRF [106, 107]. Sudo et al. conducted the first study to
demonstrate the involvement of the gut microbiome in the normal development of the HPA
axis [108]. GF mice were shown to have an exaggerated elevation of plasma adrenocorticotro-
phic hormone (ACTH) and corticosterone (the dominant glucocorticoid in rodents) in response
to stress compared to SPF mice [108, 109]. However, when Bifidobacterium infantis, a bacterial
species found in the infant gut, was inoculated in these mice, the exaggerated stress response
was normalized. Importantly, this reversal took place only when the bacterial inoculation
occurred by 6 weeks postnatum, suggesting a neurodevelopmental window of susceptibility to
the effects of this bacteria-host interaction [108].
Other studies have focused on the effect of the microbiome on behavior and brain biochemistry.
One of the challenges in interpreting the results of these reports is that they differ in animal
strain, sex, and sourcing as well as overall experimental design. Despite these differences, it is
clear that the microbiome influences both behavior and brain neurobiology. With regard to
behavior, the majority of studies that compare GF with SPF mice report a decreased anxiety-
like behavior in GF mice, in spite of an exaggerated HPA axis response to acute stress [109–
111]. The one notable exception in mice, however, was a study by Nishino et al. [112]. This
group compared GF mice with gnotobiotic mice, which are mice born in germ-free conditions
to parents fed stools of SPF mice, and found that the ex-GF mice are less anxious. In this model,
the transfer of the bacterial species Brautia coccoides reduces anxiety-like behavior [112].
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Further evidence of the microbial influence on behavior derives from transferring microbiota
between mouse strains of inherently different behavioral phenotypes. In a study by Bercik et
al. colonization of GF mice with gut bacteria from donor mice with differing anxiety pheno-
types transferred the behavioral phenotype of the donor to the recipient [113]. Again, it appears
that there is a critical neurodevelopmental time point before which behavioral profiles are
modifiable as adult GF mice colonized with SPF feces retain the anxiolytic behavioral pheno-
type of GF mice [110].
Animal studies that have investigated brain neurochemistry and examined monoamine
concentrations and turnover rates have provided some insight into explaining these behavioral
phenomena. Alterations in central monoamine neurotransmission, specifically serotonin (5-
HT), norepinephrine (NE), and dopamine (DA), are known to play a role in anxiety and
depression [114–119]. As would be predicted based on their behavioral patterns, ex-GF mice
exhibit higher NE and DA turnover rates and have higher 5-HT concentrations in the striatum
than their GF counterparts [112]. Furthermore, stress-sensitive rats that exhibit anxiety-like
behavior when GF had a reduced DA turnover in the frontal cortex, striatum, and hippocam-
pus than SPF rats [120]. Many of the studies that investigate monoamine transmission examine
tryptophan levels as well, as tryptophan is required for the synthesis of 5-HT and may be low
in depression [121]. Kynurenine, a metabolite of tryptophan, is increased in depression and
the kynurenine:tryptophan ratio in blood correlates with anxiety [103, 122, 123]. Accordingly,
the less anxious GF mice exhibit a decreased kynurenine:tryptophan ratio and increased
plasma tryptophan concentrations compared to the more-anxious SPF mice [109]. In male GF
mice, there is a significant sex-dependent increase in 5-HT and 5-hydroxyindoleacetic acid (5-
HIAA) concentrations. Notably, the reduced anxiety seen in GF animals is normalized
following microbial colonization as well as normalization of both the tryptophan concentra-
tions and the kynurenine:tryptophan ratio. Interestingly, however, the increased 5-HT and 5-
HIAA concentration in GF animals remains resistant to colonization [109]. Using mass
spectrometry, Matsumoto et al. analyzed the cerebral metabolome of GF mice and ex-GF mice
and identified 38 metabolites that differed significantly [124]. Notably, concentrations of DA
were twofold higher in GF than in ex-GF mice; consistent with the findings that GF mice display
increased motor activity and reduced anxiety-like behavior compared with their ex-GF
counterparts. In the cerebrum of GF mice, the concentration of tryptophan was decreased but
the study failed to find differences in 5-HT levels.
Various receptors, with known roles in depression and anxiety, are influenced by the micro-
biome. For instance, the 5HT1A receptor, which is associated with anxiety, has decreased
expression in the dentate granule layer of the hippocampus in GF female mice [111]. The N-
methyl-D-aspartate (NMDA) receptors are important for learning and memory. Sudo et al.
reported downregulation in the NMDA receptor subunit 2A (NR2A) mRNA in the cortex and
the hippocampus of GF mice compared to SPF mice [108]. Neufeld et al., however, did not
detect differences in the hippocampal subregions by in situ hybridization but rather demon-
strated a decrease in NMDA receptor subunit 2B (NR2B) mRNA expression in the central
amygdala of GF mice [111]. Additionally, DA D1 receptor mRNA was significantly higher in
the hippocampus of GF mice than in SPF mice [110].
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In patients with depression, hippocampal neurogenesis is reduced along with levels of BDNF,
and recent evidence indicates that increased hippocampal BDNF is associated with anxiolytic
and antidepressant behavior [125]. In the studies of GF mice, the exact influence of the
microbiome on BDNF is uncertain; some studies show increased hippocampal BDNF expres-
sion, while others show the opposite at both the mRNA and protein level. The differences in
BDNF appear to be sex-related, with reductions in BDNF being observed mainly in male GF
animals, and not in female animals [108, 109, 111]. Heijtz et al. showed that in GF mice, mRNA
expression of nerve growth factor-inducible clone A (NGFI-A), implicated in the development
of anxiety-like behavior, was significantly lower in the orbital frontal cortex, striatum, hippo-
campus, dentate gyrus, and amygdala compared with SPF mice [110]. These studies highlight
a role for neurotrophic factors in the microbiome-gut-brain axis and its influence on anxiety
and depression and further indicate that regulation of this axis may be sex dependent. The
microbiome also appears to have a broader impact on neurobiology, as evidenced by a study
looking at the amygdala that showed an altered transcriptome in GF compared to SPF mice.
Specifically, in GF mice, there is upregulation of immediate early response genes with
differential expression of genes involved in neurotransmission, plasticity, and metabolism
[126].
4.1. Treatments that alter the microbial flora
4.1.1. Probiotics
Associations between the microbiome and behavior are reinforced by studies using probiotic
therapy, which alter the gut microbial environment through the ingestion of live bacterial
cultures. There is increasing evidence that certain strains are able to attenuate various behav-
ioral and biochemical effects of stress. Adult rats given Lactobacillus helveticus NS8 display
reduced stress-induced anxiety and depression that is comparable to citalopram therapy [127].
Biochemically, these rats had lower corticosterone and ACTH concentrations in the plasma,
increased hippocampal monoamine concentrations and BDNF transcription as well as higher
levels of plasma IL-10, which is an anti-inflammatory cytokine that is reduced in depressed
patients [127]. Similarly, the probiotic formulation of L. helveticus R0052 and B. longum R0175
attenuated the response to chronic stress, with decreased levels of corticosterone, epinephrine,
and NE within the plasma [128]. Furthermore, the probiotics B. longum 1714 and B. breve 1205
are anxiolytic in mice [129]. Probiotics with B. infantis, previously discussed as being capable
of reversing the exaggerated stress response in GF mice, have shown various results in rats;
one showed attenuation of behavioral and biochemical abnormalities associated with maternal
separation, whilst another showed minimal behavioral effects, despite changes in the levels of
various cytokines and metabolites [130, 131].
Chronic treatment with L. rhamnosus (JB-1) in mice lowered stress-induced corticosterone as
well as anxiety- and depression-related behavior and caused alterations in Gamma-Amino-
butyric acid [GABA(B1b) and GABA(Aα2)] receptor mRNA in specific regions within the
brain [132]. Interestingly, these findings were not found in vagotomized mice [132]. The vagus
is known to mediate communication between the gut microbiota and the HPA axis, with
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increased CRF mRNA, plasma ACTH, and corticosterone concentrations in rodents following
vagal stimulation [133]. Furthermore, in humans, vagal nerve stimulation has antidepressant
effects, including normalization of the HPA axis [134, 135]. In mice, JB-1 increased the firing
rate of the mesenteric nerve bundle, which was prevented by subdiaphragmatic vagotomy
[133]. Similarly, in a mouse model in which chronic mild DSS colitis induces anxiety-like
behavior, B. longum NCC3001 normalized the anxiety-like behavior and CNS changes induced
by chronic gut inflammation but not in mice that had undergone vagotomy [136]. Similar
results were obtained in a T. muris parasite model of chronic colonic infection, further sup-
porting a neurally mediated mechanism of the probiotic effect [103].
From an immunological perspective, Smith et al. demonstrated that Recombination activating
gene‐1 (Rag1) knockout mice, which are B and T cell deficient, had a dysbiosis, altered behavior,
and heightened HPA axis activity [137]. When pretreatment with L. rhamnosus (R0011) and L.
helveticus (R0052) was administered, the microbiota and behavioral changes were normalized
[137]. In rats, myocardial infarction (MI) is accompanied by increased cellular apoptosis in the
limbic system and a depression-like behavior [138]. In this model, administration of probiotics
that combined L. helveticusand B. longum ameliorated post-MI depression through reduction
in pro-inflammatory cytokines and restoration of barrier integrity in the GI tract [139].
Interestingly, using the IL-10 knockout mouse, which is a model of colonic inflammation
similar to IBD, Ohland et al. showed that the ingested diet and the presence or absence of
inflammation within the GI tract can influence probiotic efficacy [140]. This suggests a role for
immune cells in the intestinal and behavioral health in rodents. Collectively, these studies
overwhelmingly support a role for probiotic strains in modulating various aspects of brain
function and behavior, some of which appear to be at least partly vagal dependent.
4.1.2. Prebiotics
Prebiotics are food components that modulate the microbiota by enhancing the growth of
probiotic microbes and have been used in several studies to further define a role for the
microbiome in behavior. Human milk oligosaccharides (HMO) promote the growth of specific
bacteria including probiotic members of the genus Bifidobacterium and Lactobacillus. Mice fed
the prebiotic containing the human milk oligosaccharides 3′Sialyllactose (3′SL) or 6′Sialyllac-
tose (6′SL) showed less anxiety-like behavior, and less microbiota alteration in response to
stress [141]. The prebiotics, fructo-oligosaccharide (FOS), and galacto-oligosaccharides (GOS)
promoted the growth of the Lactobacilli and Bifidobacteria in the gut and raised hippocampal
BDNF and NR1 subunit expression compared with controls. GOS also increases hippocampal
NR2A subunits and NR1 expression within the frontal cortex and increases plasma D-alanine,
which acts as an agonist at the NMDA receptor [142]. These studies show that prebiotic-
mediated proliferation of gut microbiota, like probiotics, can affect brain neurochemistry and
animal behavior.
4.1.3. Antimicrobials
Administration of oral, but not intraperitoneal, antimicrobials (neomycin, bacitracin, and pi-
maricin) to SPF mice increased the proportion of Lactobacilli and Actinobacteria populations,
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while decreasing the proportion of γ‐proteobacteria and Bacteroidetes populations [113]. These
microbiota changes were associated with improvements in standardized tests of less appre-
hensive behavior, effects that were reversible after discontinuation of antimicrobial treat-
ment and return to pretreatment microbiota profiles. These changes were independent of
inflammation, levels of gastrointestinal neurotransmitters, and nervous system integrity.
4.2. Evidence from human studies
4.2.1. Microbial diversity among different populations
Cross-sectional studies in humans have begun to investigate the gut microbial composition
and its association with mood. Naseribafrouei et al. analyzed fecal samples from patients
with depression and controls and found no overall significant difference in species diversity
between depressed and non-depressed samples but rather a general overrepresentation of
the order Bacteroidales in depression and a decrease in family Lachnospiraceae [143]. At a ge-
nus level, Alistipes and Oscillibacter were associated with depression. Jiang et al. analyzed
fecal samples from patients with active major depressive disorder (active-MDD), responded
major depressive disorder (responded-MDD) and healthy controls. In contrast to the first
study, Jiang et al. found increased fecal bacterial α-diversity in the active-MDD group when
compared with controls; however, this was not found between the responded-MDD when
compared with controls [144]. The three dominant phyla Bacteroidetes, Proteobacteria, and Ac‐
tinobacteria were increased, while Firmicutes were significantly reduced in both active-MDD
and responded-MDD groups than in controls. Faecalibacterium was associated with a nega-
tive correlation with the severity of depressive symptoms. Concordant with Naseribafrouei
et al., an increase in Oscillibacter and Alistipes was found in depression compared to controls
[144]. Of note, possible confounding elements to explain the differences between these two
studies may be related to the recruitment of controls from an outpatient neurology clinic by
Naseribafrouei et al., unlike Jiang who recruited healthy subjects as controls [143, 144]. Ad-
ditionally, differences between ages of subjects as well as geographic locations between the
studies could contribute to differences in bacterial diversity, as diversity of gut bacteria is
known to be influenced by several factors including health status, age, diet, and antibiotic
use [47]. In a cross-sectional observational study examining associations between the gut
microbiome and maternally rated temperament in toddlers, it was found that certain dimen-
sions of temperament could be associated with differences in phylogenetic diversity [145].
In addition, they found certain sex-specific associations between temperament and the gut
microbiome.
These studies begin to identify bacterial groups potentially harmful in the pathogenesis
of mood disorders, though further studies will be needed to elucidate temporal and
causal relationships between gut microbiota and depression as well as to evaluate their
utility as biomarkers of disease. Again, as in the rodent studies, these results point to
sex-related differences in how the microbiome may be regulated and how it affects the
CNS and behavior.
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4.2.2. Human probiotic studies
To date, few probiotic studies have been conducted in humans to evaluate their effects on
mood. The consumption of a 3-week course of a yogurt containing Lactobacillus casei Shirota
(LcS) improved mood in patients with low mood (as evaluated by a questionnaire-based
assessment) [146]. In healthy volunteers who received a 30-day course of L. helveticus R0052
and B. longum R0175 compared to placebo, probiotic-treated subjects displayed lower soma-
tization, depression, and anger hostility [147]. A study by Steenbergen et al. aimed to com-
plement these findings and showed that participants who received a multispecies probiotic
had reduced cognitive reactivity to sad mood [148]. In a randomized double-blind placebo
trial with chronic fatigue syndrome (CFS) patients, two months of daily LcS induced a
significant rise in both Lactobacillus and Bifidobacterium and a concomitant significant decrease
in anxiety symptoms compared to controls [149]. These results provide evidence that the intake
of probiotics may help reduce negative thoughts associated with sad mood. Probiotic supple-
mentation warrants further research as a potential treatment or preventative strategy for
depression.
5. Perspectives
The topics discussed in this review emphasize the broad influence that the microbiome has in
a wide range of psychiatric and neurologic diseases. Changes in the microbiome are relevant
to many brain diseases and understanding what the abnormal changes in the GI microflora
are in these conditions is necessary to identify novel targets for therapies. Recognition of
pathological changes in the constitution of the microbiome offers a possible means of antici-
pating or prognosticating future disease. It also provides an opportunity to intervene and
correct a dysbiosis with beneficial effects on the disease.
The role of the microbiome in neurodevelopment cannot be underestimated. As previously
discussed, exposure to particular microorganisms at specific time points in animal models can
have lasting impacts on neurological disease risk and behavior. Treatments that alter the
microbial flora may influence healthy brain development and further work in this area is
needed to appreciate how significant this may be in humans.
Future work that expands on our current understanding of the dysbioses that occur in CNS
diseases should hopefully provide further insight into microbiota-related disease mechanisms
and provide additional therapeutic options for patients.
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